Heilbronn, Germany
ProtaGene, founded in 1997 and headquartered in Germany, is a front-runner in providing analytic services for biologics and cell therapies. They offer comprehensive protein and gene analytic solutions to the biopharmaceutical and gene therapy industries.
The company emerged from the merger of Protagen Protein Services in Europe and BioAnalytix in the US, with a subsequent integration of GeneWerk's expertise in vector safety, integration site analysis, and bioinformatics in 2021. This merger solidified ProtaGene's position as a market leader in the analytical domain.
The company's strategic growth is underscored by a recent Growth Equity VC investment on 01 November 2023 by Ampersand Capital Partners. Operating across four sites in Europe and North America, ProtaGene collaborates with leading entities in advanced therapeutic platforms.
Investors may find ProtaGene's established history, strategic mergers, and recent funding as indicators of its robust market position and growth potential in the evolving biopharma landscape.
